Rhythm Pharmaceuticals Announces Multiple New Data Presentations from MC4R Agonists in Acquired Hypothalamic Obesity (HO), Bardet-Biedl Syndrome (BBS) and Prader-Willi Syndrome (PWS) at ENDO 2026
Rhythm Pharmaceuticals announced new clinical and real-world data presentations at ENDO 2026 showcasing the efficacy and safety of their MC4R agonists, including setmelanotide and bivamelagon, across rare obesity-related diseases such as acquired hypothalamic obesity (HO), Bardet-Biedl syndrome (BBS), and Prader-Willi syndrome (PWS). The data demon…